EXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that it will transfer its U.S. stock exchange listing from the NYSE MKT to The NASDAQ Capital Market. The Company expects its securities to cease trading on the NYSE MKT effective at the close of business on August 28, 2014 and to commence trading on NASDAQ on August 29, 2014 when the market opens. The company will retain its current ticker symbol, “FCSC,” when trading begins on NASDAQ.
Help employers find you! Check out all the jobs and post your resume.
